Burjeel Holdings, a prominent super-specialty healthcare provider in the MENA region, has announced a strategic partnership with Paige, a leading US-based company in next-generation AI technology. This collaboration aims to improve access to advanced cancer diagnostics by implementing Paige’s AI-powered solutions throughout Burjeel’s extensive healthcare network. The partnership also seeks to tackle the global shortage of pathologists and to expedite access to swift and reliable cancer diagnostics, particularly benefiting underserved communities and emerging markets.

The announcement of this collaboration took place during Abu Dhabi Global Health Week, attended by Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings. Paige has developed a range of AI applications that assist in diagnostic decision-making within cancer pathology. A notable component of this suite is Paige Prostate Detect*, recognized as the first FDA-approved AI algorithm for detecting prostate cancer in core-needle biopsies. Through this partnership, Burjeel Holdings will be among the first in the region to provide these innovative AI diagnostic tools, reinforcing its dedication to delivering timely and accessible cancer care.

Paige’s AI solutions are crafted to enhance the capabilities of pathologists, streamline workflows, and increase diagnostic confidence, which ultimately contributes to improved patient outcomes. This partnership signifies a crucial advancement towards democratizing access to advanced healthcare, ensuring that cutting-edge technologies are available to patients who need them most. John Sunil, Group CEO of Burjeel Holdings, emphasized that this collaboration represents a transformative step in delivering cancer diagnostics across their network, aiming to improve the speed and precision of cancer diagnoses for more effective treatment decisions.

Paige has achieved multiple regulatory milestones in AI for pathology, including FDA Breakthrough Device Designation for its products like Paige PanCancer Detect, Paige Breast Lymph Node, and Paige Prostate Detect. Burjeel Holdings will implement these AI applications alongside Paige OmniScreen, which screens over 1 600 molecular biomarkers to support comprehensive cancer diagnoses and more personalized treatment plans. Peter Hamilton, General Manager of Diagnostics at Paige, noted that Burjeel Holdings’ commitment to innovation and equitable care positions them as a powerful ally in closing diagnostic gaps, allowing the rapid delivery of AI technology benefits to more patients.

This partnership marks a significant milestone for Burjeel Holdings, positioning the organization as a regional hub for AI-enabled pathology with the potential to expand this transformative technology throughout MENA and beyond.